v3.26.1
Income taxes - Reconciliation of the Company's total tax using the statutory income tax rate (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Reconciliation of income taxes (Amount):    
Pre-tax loss $ (18,214) $ (29,397)
U.S. federal statutory tax rate (3,824) (6,173)
Tax credits:    
Research and development credits (2,597)  
Orphan drug tax credit (6,010)  
Change in valuation allowance 11,372 5,735
Nontaxable or nondeductible items:    
Debt extinguishment (380)  
Change in fair value of debt 1,038  
Transaction costs 344  
Stock-based compensation (82) 25
Disallowed interest expense 137 412
Other 2 1
Effective income tax expense (benefit) - Amount $ 0 $ 0
Tax Jurisdiction of Domicile [Extensible Enumeration] UNITED STATES UNITED STATES
Reconciliation of income taxes (Percentage):    
U.S. federal statutory rate 21.00% 21.00%
Tax credits:    
Research and development credits 14.30%  
Orphan drug tax credit 33.00%  
Change in valuation allowance (62.50%) (19.50%)
Nontaxable or nondeductible items:    
Debt extinguishment 2.10%  
Change in fair value of debt (5.70%)  
Transaction costs (1.90%)  
Stock-based compensation 0.50% (0.10%)
Disallowed interest expense (0.80%) (1.40%)
Other
Effective income tax expense (benefit) - Percentage